| Title |
Intravitreal vascular endothelial growth factor (VEGF) inhibitor injection in unrecognised early pregnancy
|
|---|---|
| Published in |
Investigational New Drugs, June 2016
|
| DOI | 10.1007/s10637-016-0361-8 |
| Pubmed ID | |
| Authors |
Farzan Kianersi, Heshmatollah Ghanbari, Zahra Naderi Beni, Afsaneh Naderi Beni |
| Abstract |
The use of intravitreal vascular endothelial growth factor (VEGF) inhibitor medications has widened considerably to include indications affecting females of reproductive age. Our patient was inadvertently exposed to bevacizumab within the first trimester when placental growth and fetal organogenesis take place and patient suffered pregnancy loss. There is insufficient information to suggest that such use is safe, nor is there definitive evidence to suggest that it causes harm. We advise that ophthalmologists discuss pregnancy with women of childbearing age undergoing intraocular anti-VEGF injections and in pregnant woman counselling is needed to explain the potential risks and benefits. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 39 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 39 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 6 | 15% |
| Other | 5 | 13% |
| Student > Master | 5 | 13% |
| Student > Bachelor | 3 | 8% |
| Unspecified | 2 | 5% |
| Other | 4 | 10% |
| Unknown | 14 | 36% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 15 | 38% |
| Unspecified | 2 | 5% |
| Agricultural and Biological Sciences | 2 | 5% |
| Biochemistry, Genetics and Molecular Biology | 1 | 3% |
| Computer Science | 1 | 3% |
| Other | 1 | 3% |
| Unknown | 17 | 44% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 03 June 2016.
All research outputs
#20,332,117
of 22,876,619 outputs
Outputs from Investigational New Drugs
#975
of 1,168 outputs
Outputs of similar age
#291,812
of 339,291 outputs
Outputs of similar age from Investigational New Drugs
#7
of 11 outputs
Altmetric has tracked 22,876,619 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,168 research outputs from this source. They receive a mean Attention Score of 4.7. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 339,291 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 11 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.